Basal-bolus insulin therapy is recommended for patients with poorly controlled type 2
diabetes (T2D) and HbA1c >9%. However, basal-bolus insulin is labor intensive and associated
with increased risk of hypoglycemia, glycemic variability, weight gain and poor compliance.
Thus, there is a critical need for a simpler treatment regimen that could overcome these
limitations. IDegLira, a fixed-ratio combination (FRC) therapy consisting of insulin degludec
and liraglutide, is an attractive option for this population given its proven benefits on
glycemic control, weight and compliance. This study aims to show that a simpler regimen using
a novel FRC agent (IDegLira) can improve glycemic control, decrease hypoglycemia, reduce the
burden of diabetes care, and improve satisfaction/adherence in patients with poorly
controlled T2D with HbA1c between ≥ 9-12%. This open-label, treat-to- target, two-arm
parallel, controlled trial will randomize participants with T2D and HbA1c ≥ 9%, treated with
oral anti-diabetic agents and/or basal insulin therapy to lDegLira or basal-bolus insulin for
26 weeks.